Tetrandrine may treat membranous glomerulopathy via P13K/Akt signaling pathway regulation: therapeutic mechanism validation using Heymann nephritis rat model

References

• Taherkhani A, Kalantari S, Arefi Oskouie A, et al. Network analysis of membranous glomerulonephritis based on metabolomics data. Mol Med Rep. 2018;18:4197–4212.
   PubMed Web of Science ®Google Scholar
• Barbari A. Pre- and posttransplant refractory idiopathic membranous glomerulonephritis: the forgotten potential culprit. Exp Clin Transplant. 2017;15:483–489.
   PubMed Web of Science ®Google Scholar
• Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int. 2001;59(5):1983–1994.
   PubMed Web of Science ®Google Scholar
• Ponticelli C. Membranous nephropathy. J Nephrol. 2007;20:268–287.
   PubMed Web of Science ®Google Scholar
• Tian R, Wang L, Chen A, et al. Sanqi oral solution ameliorates renal damage and restores podocyte injury in experimental membranous nephropathy via suppression of NFkappaB. Biomed Pharmacother. 2019;115:108904.
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Wetzels JF. Alkylating agents in membranous nephropathy: efficacy proven beyond doubt. Nephrol Dialysis Trans. 2010;25(6):1760–1766.
   PubMed Web of Science ®Google Scholar
• du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. Am J Kidney Dis. 2005;46(6):1012–1029.
   PubMed Web of Science ®Google Scholar
• Wu CC, Chen JS, Chen SJ, et al. Kinetics of adaptive immunity to cationic bovine serum albumin-induced membranous nephropathy. Kidney Int. 2007;72(7):831–840.
   PubMed Web of Science ®Google Scholar
• Nie L. Clincal experience in TCM treatment of refractory nephrotic syndrome. J Tradit Chin Med. 2008;28(1):46–48.
   PubMedGoogle Scholar
• Guo X, Cai Y, Sun G, et al. Effects of Fuzheng Qufeng Recipe on proteinuria and renal pathological changes in rats with membranous nephropathy. Chinese experimental prescription. 2018;24. 136–141.
   Google Scholar
• Xi Y, Zhang HJ, Ye ZG, et al. [Research development on modern pharmacological effect of tetrandrine]. Zhongguo Zhong Yao Za Zhi. 2020;45:20–28.
   PubMedGoogle Scholar
• Liu X, Zhou QG, Zhu XC, et al. Screening for potential active components of Fangji Huangqi Tang on the Treatment of nephrotic syndrome by using integrated metabolomics based on “correlations between chemical and metabolic profiles”. Front Pharmacol. 2019;10:1261.
   PubMed Web of Science ®Google Scholar
• Perez RM. Anti-inflammatory activity of compounds isolated from plants. ScientificWorldJournal. 2001;1:713–784.
   PubMedGoogle Scholar
• Choi HS, Kim HS, Min KR, et al. Anti-inflammatory effects of fangchinoline and tetrandrine. J Ethnopharmacol. 2000;69(2):173–179.
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–690.
   PubMed Web of Science ®Google Scholar
• Lee WY, Lee CY, Kim YS, et al. The methodological trends of traditional herbal medicine employing network pharmacology. Biomolecules. 2019;99(8):362. doi: 10.3390/biom9080362.
   PubMed Web of Science ®Google Scholar
• Liu B, Song Z, Yu J, et al. The atherosclerosis-ameliorating effects and molecular mechanisms of BuYangHuanWu decoction. Biomed Pharmacother. 2020;123:109664.
   PubMed Web of Science ®Google Scholar
• Rappaport N, Twik M, Plaschkes I, et al. MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search. Nucleic Acids Res. 2017;45:D877–D87.
   PubMed Web of Science ®Google Scholar
• Wang X, Shen Y, Wang S, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45(W1):W356–W60.
   PubMed Web of Science ®Google Scholar
• Qin L, Chen H, Ding X, et al. Utilizing network pharmacology to explore potential mechanisms of YiSui NongJian formula in treating myelodysplastic syndrome. Bioengineered. 2021;12(1):2238–2252.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(D1):D447–52.
   PubMed Web of Science ®Google Scholar
• Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6(1):13.
   PubMed Web of Science ®Google Scholar
• Di TQ, Jin J, Hu X, et al. Curcumin Improves the renal autophagy in rat experimental membranous nephropathy via regulating the PI3K/AKT/mTOR and Nrf2/HO-1 signaling pathways. Biomed Res Int. 2020;2020:7069052.
   PubMed Web of Science ®Google Scholar
• Kjl A, Tdsjm B. Analysis of relative gene expression data using Real-Time quantitative PCR and the 2 ΔΔ C T method. Methods. 2001;25(4):402–408.
   PubMed Web of Science ®Google Scholar
• Beck LH Jr., Fervenza FC, Beck DM, et al. Rituximab-Induced depletion of Anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543–1550.
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Wetzels JF. Management of patients with membranous nephropathy. Nephrol Dialysis Trans. 2012;27(1):6–9.
   PubMed Web of Science ®Google Scholar
• Waldman M, Austin HA. 3rd. Controversies in the treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2009;5(8):469–479.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Passerini P. Management of idiopathic membranous nephropathy. Expert Opin Pharmacother. 2010;11(13):2163–2175.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Liao G, Li Y, et al. The efficacy and safety of rituximab in treating childhood refractory nephrotic syndrome: a meta-analysis. Sci Rep. 2015;5(1):8219.
   PubMed Web of Science ®Google Scholar
• Sprangers B, Lefkowitz GI, Cohen SD, et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin J Am Soc Nephrol. 2010;5(5):790–797.
   PubMed Web of Science ®Google Scholar
• Van Den Brand JA, van Dijk PR, Hofstra JM, et al. Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2014;9(6):1066–1073.
   PubMed Web of Science ®Google Scholar
• Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35:100–105.
   PubMed Web of Science ®Google Scholar
• Elvin J, Buvall L, Lindskog Jonsson A, et al. Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation. Am J Physiol Renal Physiol. 2016;310(9):F846–56.
   PubMed Web of Science ®Google Scholar
• Ha TS, Park HY, Seong SB, et al. Puromycin aminonucleoside increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner. Exp Cell Res. 2016;340(1):139–149.
   PubMed Web of Science ®Google Scholar
• Vacas E, Bajo AM, Schally AV, et al. Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells. Peptides. 2012;38(2):275–281.
   PubMed Web of Science ®Google Scholar
• Begenik H, Soyoral YU, Erkoc R, et al. Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome. Redox Rep. 2013;18(3):107–112.
   PubMed Web of Science ®Google Scholar
• Soyoral YU, Aslan M, Emre H, et al. Serum paraoxonase activity and oxidative stress in patients with adult nephrotic syndrome. Atherosclerosis. 2011;218(1):243–246.
   PubMed Web of Science ®Google Scholar
• Rysz J, Banach M, Cialkowska-Rysz A, et al. Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell Mol Immunol. 2006;3:151–154.
   PubMed Web of Science ®Google Scholar
• Zhang B, Xie S, Shi W, et al. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dialysis Trans. 2012;27(5):1746–1755.
   PubMed Web of Science ®Google Scholar
• Fukuda A, Wickman LT, Venkatareddy MP, et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int. 2012;81(1):40–55.
   PubMed Web of Science ®Google Scholar
• Tryggvason K, Pikkarainen T, Patrakka J. Nck links nephrin to actin in kidney podocytes. Cell. 2006;125(2):221–224.
   PubMed Web of Science ®Google Scholar
• Fauchald P, Albrechtsen D, Leivestad T, et al. Renal replacement therapy in patients over 60 years of age. Transplant Proc. 1988;20:432–433.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhu C, Yin J, et al. Tetrandrine suppresses transient receptor potential cation channel protein 6 Overexpression- Induced Podocyte damage via blockage of RhoA/ROCK1 Signaling. Drug Des Devel Ther. 2020;14:361–370.
   PubMed Web of Science ®Google Scholar
• Faour WH, Thibodeau JF, Kennedy CR. Mechanical stretch and prostaglandin E2 modulate critical signaling pathways in mouse podocytes. Cell Signal. 2010;22(8):1222–1230.
   PubMed Web of Science ®Google Scholar
• Mahimainathan L, Das F, Venkatesan B, et al. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes. 2006;55(7):2115–2125.
   PubMed Web of Science ®Google Scholar
• Li Z, Hong X, Ping Y, et al. Angiotensin AT1 receptor activation mediates high glucose-induced epithelial–mesenchymal transition in renal proximal tubular cells. 2010;37: e152-7.
   Google Scholar
• Li D, Lu Z, Xu Z, et al. Spironolactone promotes autophagy via inhibiting PI3K/AKT/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress. Biosci Rep. 2016;36(4):e00355. doi: 10.1042/BSR20160086.
   Web of Science ®Google Scholar